Home » Newsletters » BioWorld Science

BioWorld Science

June 17, 2020

View Archived Issues

Lifespan synaptic atlas gives developmental insights

Prozac for infectious disease

Staten begins first-in-human study of STT-5058 for hypertriglyceridemia

Phase IIa data reported for Sym-015 in non-small cell lung cancer patients

KAND-567 demonstrates positive effect on mobility in a preclinical model of spinal cord injury

MK-1092 demonstrates safety and promising glucose-lowering activity

Phase Ib data for ningetinib and gefitinib in EGFR-TKI-resistant NSCLC

Positive data reported from phase II AFFIRM-35 study of ABY-035

First patient dosed in dose-expansion stage of phase Ib/II trial of cavrotolimod

Bisantrene phase II study in AML yields positive results

Pfizer describes new hemoglobin subunit beta polymerization inhibitors

New PCSK9 inhibitors discovered at Novartis

BioVersys synthesizes compounds interacting with accessory gene regulator A

Vyome releases positive phase II results for VB-1953

3M Pharmaceuticals patents cytokine biosynthesis inducers

Netakimab demonstrates superiority to placebo in second-line psoriatic arthritis

TOPADUR Pharma presents dual PDE5A inhibitors/soluble guanylate cyclase activators

Health Canada approves initiation of COVID-19 study of EB-05

New therapeutic target identified for emphysema in COPD

Syndrome with oculo-cerebral anomalies connected to PLXNA1 gene variants

Ilaris approved in U.S. for active Still's disease

FDA approves Cosentyx for active nonradiographic axial spondyloarthritis

FDA clears start of phase II trial of Metablok to prevent acute lung and kidney injury in COVID-19

Phase I results reported for BTK inhibitor TG-1701 in relapsed/refractory B-cell malignancies

Phase II study of APG-1387 for chronic hepatitis B doses first patient

FDA accepts IND for investigator-initiated trial of ATI-450 in hospitalized patients with COVID-19

Sinopharm's COVID-19 vaccine produces high-titer antibodies in phase I/II study

FDA allows Hookipa to study HB-202 with HB-201 for HPV-positive cancers

FDA clears initiation of phase II/III study of PTC-299 for COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...